HDR Prostate Brachytherapy.
暂无分享,去创建一个
[1] T. Pugh,et al. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. , 2013, Brachytherapy.
[2] Peter Bownes,et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] A novel method for accurate needle-tip identification in trans-rectal ultrasound-based high-dose-rate prostate brachytherapy. , 2011, Brachytherapy.
[4] É. Vigneault,et al. High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] M. Kattan,et al. High‐dose rate brachytherapy compared with open radical prostatectomy for the treatment of high‐risk prostate cancer: 10 year biochemical freedom from relapse , 2012, BJU international.
[6] M. Chatfield,et al. HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre , 2012, Journal of medical imaging and radiation oncology.
[7] Deidre Batchelar,et al. A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants. , 2013, Brachytherapy.
[8] Howard Pai,et al. Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer , 2013, Cancer.
[9] Juan Cardenal,et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] R. Galalae,et al. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone? , 2014, Brachytherapy.
[11] Hong Ye,et al. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer. , 2016, International journal of radiation oncology, biology, physics.
[12] H. Samaratunga,et al. Long‐term outcomes of high‐dose‐rate brachytherapy for intermediate‐ and high‐risk prostate cancer with a median follow‐up of 10 years , 2017, BJU international.
[13] P. Prada,et al. Biochemical outcome after high‐dose‐rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience , 2012, BJU international.
[14] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[15] P. Hoskin,et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] Dimos Baltas,et al. High dose rate brachytherapy as monotherapy for localised prostate cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] F. Vicini,et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. , 2011, International journal of radiation oncology, biology, physics.
[18] A. D'Amico,et al. Long‐term outcomes of partial prostate treatment with magnetic resonance imaging‐guided brachytherapy for patients with favorable‐risk prostate cancer , 2018, Cancer.
[19] C. Kirisits,et al. Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM☆ , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] B. Carey,et al. Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study. , 2014, Brachytherapy.
[21] H. Patrocinio,et al. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results. , 2012, International journal of radiation oncology, biology, physics.
[22] J. Praag,et al. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience. , 2012, International journal of radiation oncology, biology, physics.
[23] J. Millar,et al. Urethral strictures following high-dose-rate brachytherapy for prostate cancer: analysis of risk factors. , 2013, Brachytherapy.
[24] M. Steinberg,et al. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. , 2016, International journal of radiation oncology, biology, physics.
[25] Hans T. Chung,et al. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy. , 2017, Brachytherapy.
[26] G. Morton,et al. High dose-rate brachytherapy in the treatment of prostate cancer , 2018, Translational andrology and urology.
[27] Joos V Lebesque,et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] T. Mate,et al. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. , 1998, International journal of radiation oncology, biology, physics.
[29] M. Parmar,et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.
[30] R. Pötter,et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[31] Daniel I Glazer,et al. Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review , 2016, Abdominal Radiology.
[32] I. Hsu,et al. High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. , 2008, International journal of radiation oncology, biology, physics.
[33] D Andrew Loblaw,et al. Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy. , 2011, Brachytherapy.
[34] J. Pérez-Gracia,et al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. , 2016, Brachytherapy.
[35] Deidre Batchelar,et al. Validation study of ultrasound-based high-dose-rate prostate brachytherapy planning compared with CT-based planning. , 2014, Brachytherapy.
[36] A. Pantuck,et al. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. , 2017, Brachytherapy.
[37] D. Brenner,et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .
[38] G. Gustafson,et al. High-Dose-Rate Prostate Brachytherapy: An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer , 2010, American journal of clinical oncology.
[39] P. Bogner,et al. Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy: Feasibility and Initial Experiences Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy , 2011, Pathology & Oncology Research.
[40] J. Pouliot,et al. Measurement of craniocaudal catheter displacement between fractions in computed tomography–based high dose rate brachytherapy of prostate cancer , 2007, Journal of applied clinical medical physics.
[41] P. Hoskin,et al. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[42] S. Kariya,et al. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. , 2017, Brachytherapy.
[43] The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort. , 2018, International journal of radiation oncology, biology, physics.
[44] G. Morton,et al. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique , 2014, Journal of contemporary brachytherapy.
[45] Prevention of needle displacement in multifraction high-dose-rate prostate brachytherapy: A prospective volumetric analysis and technical considerations. , 2015, Practical radiation oncology.
[46] T. Phan,et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. , 2007, The Journal of urology.
[47] M. Viergever,et al. Development and Testing of a Magnetic Resonance (MR) Conditional Afterloader for Source Tracking in Magnetic Resonance Imaging-Guided High-Dose-Rate (HDR) Brachytherapy. , 2018, International journal of radiation oncology, biology, physics.
[48] W. J. Morris,et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.
[49] M. Milette,et al. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. , 2014, Brachytherapy.
[50] G. Pond,et al. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. , 2006, Brachytherapy.
[51] P. Novaes,et al. Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. , 2008, International braz j urol : official journal of the Brazilian Society of Urology.
[52] G. Gustafson,et al. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients. , 2014, Brachytherapy.
[53] Alexandra Rink,et al. Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. , 2016, Brachytherapy.
[54] G. Gustafson,et al. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. , 1995, International journal of radiation oncology, biology, physics.
[55] J. Pouliot,et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. , 2012, Brachytherapy.
[56] Alexandra Rink,et al. Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[57] Baris Turkbey,et al. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer , 2016, CA: a cancer journal for clinicians.
[58] Wendy L. Smith,et al. Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. , 2007, International journal of radiation oncology, biology, physics.
[59] R. Stafford,et al. Prostate magnetic resonance imaging for brachytherapists: Anatomy and technique. , 2017, Brachytherapy.
[60] Á. Csomós,et al. Needle-related ultrasound artifacts and their importance in anaesthetic practice. , 2014, British journal of anaesthesia.
[61] R. Mark,et al. Interstitial High Dose Rate (HDR) Brachytherapy as Monotherapy for Early Stage Prostate Cancer: Median 8 Year Results in 312 Patients , 2010 .
[62] G. Gustafson,et al. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.
[63] J. Pouliot,et al. Early clinical experience with anatomy-based inverse planning dose optimization for high-dose-rate boost of the prostate. , 2002, International journal of radiation oncology, biology, physics.
[64] G. Morton,et al. Intraoperative ultrasound-based planning can effectively replace postoperative CT-based planning for high-dose-rate brachytherapy for prostate cancer. , 2016, Brachytherapy.
[65] Hans T. Chung,et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[66] P. Hoskin,et al. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[67] R. Kudzia,et al. High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen. , 2015, Brachytherapy.
[68] P. Unger,et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. , 2011, The Journal of urology.
[69] Y. Yoshioka,et al. High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up. , 2016, International journal of radiation oncology, biology, physics.
[70] Rick Chappell,et al. Is α/β for prostate tumors really low? , 2001 .
[71] P. Carroll,et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. , 2012, International journal of radiation oncology, biology, physics.
[72] Liying Zhang,et al. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).
[73] P. Ágoston,et al. Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. , 2011, Brachytherapy.
[74] S. van Dyk,et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.
[75] Hans T. Chung,et al. High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[76] Y. Yamada,et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. , 2008, Brachytherapy.
[77] J. Williamson,et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .
[78] A. Kishan,et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. , 2017, European urology.
[79] J. Logue,et al. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[80] J. Millar,et al. High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. , 2010, Brachytherapy.
[81] Blasko,et al. Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.
[82] P. Hoskin,et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[83] Dimos Baltas,et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. , 2013, International journal of radiation oncology, biology, physics.
[84] Y. Yamada,et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. , 2013, Brachytherapy.
[85] Kari Tanderup,et al. Learning curve of MRI-based planning for high-dose-rate brachytherapy for prostate cancer. , 2016, Brachytherapy.
[86] Lei Dong,et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[87] Frank-André Siebert,et al. Imaging of implant needles for real-time HDR-brachytherapy prostate treatment using biplane ultrasound transducers. , 2009, Medical physics.
[88] J. Chin,et al. Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.